Brief: ADC Therapeutics Announces Updates On Lotis-7 Clinical Trial Evaluating Zynlonta® In Combination With Glofitamab Or Mosunetuzumab In Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

ADC Therapeutics SA

04/04/2024 12:26

April 4 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES UPDATES ON LOTIS-7 CLINICAL
TRIAL
EVALUATING ZYNLONTA® IN COMBINATION WITH GLOFITAMAB OR
MOSUNETUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL
NON-HODGKIN LYMPHOMA
    * ADC THERAPEUTICS SA -  IN DOSE ESCALATION PORTION (PART 1)
OF
LOTIS-7, NO DOSE-LIMITING TOXICITIES WERE OBSERVED ACROSS ALL
PATIENTS

Source text for Eikon:  ID:nGNX9qQGzL 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))